Table 3 Drug selection strategy for PD patients under specific circumstances among doctors from different levels of hospitals and cities
Items | Non-tertiary hospitals (n=147) | Tertiary hospitals (n=342) | P value | Non-capital cities (n=259) | Capital cities (n=230) | P value |
|---|---|---|---|---|---|---|
Age < 65 years without cognitive impairment | ||||||
Levodopa | 60(40.8%) | 104(30.4%) | 0.025 | 102(39.4%) | 62(27.0%) | 0.004 |
Dopamine agonists | 47(32.0%) | 163(47.7%) | 0.001 | 77(29.7%) | 133(57.8%) | 0.000 |
MAO-B inhibitors | 15(10.2%) | 47(13.7%) | 0.282 | 22(8.5%) | 40(17.4%) | 0.003 |
Age > 65 years or with cognitive impairment | ||||||
Levodopa | 86(58.5%) | 191(55.8%) | 0.587 | 127(49.0%) | 150(65.2%) | 0.000 |
Dopamine agonists | 17(11.6%) | 97(28.4%) | 0.000 | 45(17.4%) | 69(30.0%) | 0.001 |
MAO-B inhibitors | 12(8.2%) | 29(8.5%) | 0.908 | 19(7.3%) | 22(9.6%) | 0.375 |
Wearing-off phenomenon | ||||||
Add levodopa frequency | 44(29.9%) | 143(41.8%) | 0.013 | 67(25.9%) | 120(52.2%) | 0.000 |
Switch to CR levodopa | 67(45.6%) | 169(49.4%) | 0.436 | 106(40.9%) | 130(56.5%) | 0.001 |
Add COMT or MAO-B inhibitors | 54(36.7%) | 149(43.6%) | 0.160 | 85(32.8%) | 118(51.3%) | 0.000 |
Add dopamine agonists | 58(39.5%) | 138(40.4%) | 0.853 | 81(31.3%) | 115(50.0%) | 0.000 |
Peak-dose dyskinesia | ||||||
Reduce levodopa dose, add its frequency | 55(37.4%) | 163(47.7%) | 0.037 | 91(35.1%) | 127(55.2%) | 0.000 |
Reduce levodopa dose, add dopamine agonists | 58(39.5%) | 157(45.9%) | 0.188 | 97(37.5%) | 118(51.3%) | 0.002 |
Reduce levodopa dose, add COMT inhibitors | 41(27.9%) | 104(30.4%) | 0.576 | 60(23.2%) | 85(37.0%) | 0.001 |
Add amantadine | 17(11.6%) | 54(15.8%) | 0.224 | 31(12.0%) | 40(17.4%) | 0.089 |
PD with psychosis | ||||||
Clozapine | 31(21.1%) | 81(23.7%) | 0.531 | 41(15.8%) | 71(30.9%) | 0.000 |
Olanzapine | 59(40.1%) | 165(48.2%) | 0.099 | 98(37.8%) | 126(54.8%) | 0.000 |
Quetiapine | 16(10.9%) | 90(26.3%) | 0.000 | 32(12.4%) | 74(32.2%) | 0.000 |
PD with dementia | ||||||
Huperzine A | 51(34.7%) | 73(21.3%) | 0.002 | 53(20.5%) | 71(30.9%) | 0.008 |
Donepezil | 70(47.6%) | 193(56.4%) | 0.073 | 126(48.6%) | 137(59.6%) | 0.016 |
Rivastigmine | 15(10.2%) | 67(19.6%) | 0.011 | 41(15.8%) | 41(17.8%) | 0.555 |
Memantine | 32(21.8%) | 153(44.7%) | 0.000 | 61(23.6%) | 124(53.9%) | 0.000 |
PD with depression | ||||||
Tricyclic antidepressants | 41(27.9%) | 60(17.5%) | 0.010 | 65(25.1%) | 36(15.7%) | 0.010 |
SSRIs | 86(58.5%) | 206(60.2%) | 0.721 | 144(55.6%) | 148(64.3%) | 0.049 |
Pramipexole | 40(27.2%) | 145(42.4%) | 0.001 | 62(23.9%) | 123(53.5%) | 0.000 |
PD with RLS | ||||||
Levodopa | 31(21.1%) | 92(26.9%) | 0.174 | 48(18.5%) | 75(32.6%) | 0.000 |
Dopamine agonists | 31(21.1%) | 118(34.5%) | 0.003 | 56(21.6%) | 93(40.4%) | 0.000 |
Benzodiazepines | 43(29.3%) | 97(28.4%) | 0.842 | 88(34.0%) | 52(22.6%) | 0.006 |